Effects of conjugated equine estrogen on stroke in the Women's Health Initiative

Circulation

Volumn 113, Issue 20, 2006, Pages 2425-2434

  Hendrix, Susan L ^a,o   Wassertheil Smoller, Sylvia ^b   Johnson, Karen C ^c   Howard, Barbara V ^d   Kooperberg, Charles ^e   Rossouw, Jacques E ^f   Trevisan, Maurizio ^g   Aragaki, Aaron ^e   Baird, Alison E ^h   Bray, Paul F ^j   Buring, Julie E ^k   Criqui, Michael H ^l   Herrington, David ^m   Lynch, John K ⁱ   Rapp, Stephen R ^m   Torner, James ⁿ  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

ⁱ Neuroepidemiology Branch   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

ⁿ UNIVERSITY OF IOWA   (United States)

^o HUTZEL HOSPITAL   (United States)

more..

Author keywords

Estrogen; Hormones; Stroke; Women

Indexed keywords

ACETYLSALICYLIC ACID; CONJUGATED ESTROGEN; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; STATINE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMBOLISM; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; CORONARY ARTERY DISEASE; MIDDLE AGED; PATIENT; RISK ASSESSMENT;

AGED; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DOUBLE-BLIND METHOD; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; PATIENT DROPOUTS; POSTMENOPAUSE; RISK ASSESSMENT;

EID: 33744501833     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.594077     Document Type: Article

References (34)

1. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Tex: American Heart Association; 2005.
2. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
3. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
4. Behl C, Widmann M, Trapp T, Holsboer F. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1995;216:473-482.
5. Vedder H, Teepker M, Fischer S, Krieg JC. Characterization of the neuroprotective effects of estrogens on hydrogen peroxide-induced cell death in hippocampal HT22 cells: time and dose-dependency. Exp Clin Endocrinol Diabetes. 2000;108:120-127.
6. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem. 1996;66:1836-1844.
7. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN III, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;28:289:2651-2662.
8. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;23:291:2947-2958.
9. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA. 1983;18:249:903-906.
10. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation. 1987;75:1102-1109.
11. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
13. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
14. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med. 1985;313:1038-1043.
15. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med. 1993;153:73-79.
16. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med. 1993;153:1201-1209.
17. Lemaitre R, Heckbert S, Psaty B, Smith N, Kaplan R, Tirshwell D. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med. 2002;162:1954-1960.
18. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325:756-762.
19. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
20. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
21. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ ; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
22. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701-1712.
23. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
24. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13:S78-S86.
25. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13:S18-S77.
26. Curb D, McTiernan A, Heckbert SR, Koopersberg C, Stanford J, Nevitt M, Johnson KC, Proux-Burns L, Pastore L, Criqui M, Daugherty S. Outcomes ascertainment and adjudication. Ann Epidemiol. 2003;13:122-128.
27. Bamford JM, Sandercock P, Dennis M, Burn M, Warlow C. Classification and natural history of clinically identifiable subtypes of acute cerebral infarction. Lancet. 1991;337:1521-1526.
28. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
29. Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet. 1975;1:480-484.
30. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: the Framingham Study. Stroke. 1994;25:40-43.
31. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 1993;306:956-963.
32. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab. 2000;20:631-652.
33. Sacco RL. Risk factors and outcomes for ischemic stroke. Neurology. 1995;45:S10-S14.
34. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference. IV. prevention and rehabilitation of stroke: risk factors. Stroke. 1997;28:1507-1517.